Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Godwin Akpeko Dziwornu; Henrietta Dede Attram; Samuel Gachuhi; Kelly Chibale

doi:10.1039/D0MD00062K

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Godwin Akpeko Dziwornu,

^a Henrietta Dede Attram,

^a Samuel Gachuhi

^a and Kelly Chibale

*^abcd

Author affiliations

* Corresponding authors

^a Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
E-mail: kelly.chibale@uct.ac.za
Tel: +27 21 6502553

^b Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch 7701, South Africa

^c Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa

^d South African Medical Research Council Drug Discovery and Development Research Unit, University of Cape Town, Rondebosch 7701, South Africa

Abstract

Globally, schistosomiasis threatens more than 700 million lives, mostly children, in poor localities of tropical and sub-tropical areas with morbidity due to acute and chronic pathological manifestations of the disease. After a century since the first antimonial-based drugs were introduced to treat the disease, anti-schistosomiasis drug development is again at a bottleneck with only one drug, praziquantel, available for treatment purposes. This review focuses on promising chemotypes as potential starting points in a drug discovery effort to meet the urgent need for new schistosomicides.

This article is part of the themed collection: Neglected Tropical Diseases

Download options Please wait...

Article information

DOI: https://doi.org/10.1039/D0MD00062K
Article type: Review Article
Submitted: 24 Feb 2020
Accepted: 22 Mar 2020
First published: 06 Apr 2020

Download Citation

RSC Med. Chem., 2020,11, 455-490

Permissions

Request permissions

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

G. A. Dziwornu, H. D. Attram, S. Gachuhi and K. Chibale, RSC Med. Chem., 2020, 11, 455 DOI: 10.1039/D0MD00062K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Social activity

Fetching data from CrossRef.
This may take some time to load.

RSC Medicinal Chemistry

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Abstract

Article information

Download Citation

Permissions

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Social activity

Search articles by author

Spotlight

Advertisements